Harbin Pharmaceutical Group (600664.SH) released the Q1-Q3 report for 2024, achieving revenue...
According to the Zhitong Finance APP, Harbin Pharmaceutical Group (600664.SH) released the Q1-Q3 report for 2024. During the reporting period, the company achieved revenue of 12.256 billion yuan, a year-on-year growth of 6.63%; net income attributable to shareholders of the listed company was 0.508 billion yuan, a year-on-year growth of 74.97%; net income attributable to shareholders of the listed company after deducting non-recurring gains and losses was 0.47 billion yuan, a year-on-year growth of 91.39%; basic earnings per share were 0.20 yuan/share.